1621256-07-2

Upstream product

• 89694-48-4 5-chloro-2-methoxyphenyl boronic acid 
• 105854-65-7 2-chloro-5,5-dimethylcyclohex-1-enecarbaldehyde 
• 1621255-69-3 2-(5-chloro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enecarbaldehyde 
• 1621256-06-1 (2-(5-chloro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methanol 
• 473596-87-1 4-methoxycarbonyl-2-methylbenzeneboronic acid pinacol ester 

Downstream Products

• 1621256-08-3 methyl 3'-(2-(chloromethyl)-4,4-dimethylcyclohex-1-enyl)-4'-methoxy-2-methylbiphenyl-4-carboxylate 
• 1621256-09-4 methyl 3'-(2-(((4S,5S)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4'-methoxyphenyl-2-methylbiphenyl-4-carboxylate 
• 1621255-40-0 3'-(2-(((4S,5S)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4'-methoxy-2-methylbiphenyl-4-carboxylic acid 
• 1621256-10-7 methyl 3'-(2-(((4R,5S)-5-(3,5-bis(trifluoromthyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4'-methoxyphenyl-2-methylbiphenyl-4-carboxylate 
• 1621255-41-1 3'-(2-(((4R,5S)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4'-methoxy-2-methylbiphenyl-4-carboxylic acid 
• 1621256-11-8 methyl 3'-(2-(((4R,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4'-methoxyphenyl-2-methylbiphenyl-4-carboxylate 
• 1621255-42-2 3'-(2-(((4R,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4'-methoxy-2-methylbiphenyl-4-carboxylic acid 

Relevant academic research and scientific papers

BIARYL- OR HETEROCYCLIC BIARYL-SUBSTITUTED CYCLOHEXENE DERIVATIVE COMPOUNDS AS CETP INHIBITORS

The present invention provides biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds, isomers thereof, or pharmaceutically acceptable salts. The compounds of the invention show a CETP inhibitory effect that increases HDL-cholesterol levels and reduces LDL-cholesterol levels. Pharmaceutical compositions comprising the compounds are useful for the prevention or treatment of dyslipidemia or dyslipidemia-related diseases.